

Product Data Sheet

Product Name: PROTAC ER α Degradar-1
 Cat. No.: GC34341

Chemical Properties

Cas. No. 2417369-94-7

SMILES OC1=CC=C(/C(C2=CC=C(OCCN(C)C(COCCOCCNC(C3=CC=C(C(N4[C@@H](C)[C@H](NC([C@H](C)NC)=O)C(N(CC5=C(OC)C=CC6=C5C=CC=C6)C7=C4C=C(C#N)C=C7)=O)=O)C=C3)=O)=O)C=C2)=C(C8=CC=CC=C8)\CC)C=C1

Formula C₆₆H₆₉N₇O₁₀

M.Wt 1120.29

Solubility DMSO: 200 mg/mL (178.53 mM); Water: < 0.1 mg/mL (insoluble)

Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure

Protocol

Kinase experiment:

Synthesis of a PROTAC: i. Attachment of a Linker (L2) to an E3 Ligase Binding Group (E3LB). ii. Attachment of a protein binding moiety (PB) to an E3LB via a Linker (L2)[1].

References:

[1]. Thomas Pillow, et al. Protac antibody conjugates and methods of use. WO2017201449A1.

Background

PROTAC ER α Degradar-1 comprises an ubiquitin E3 ligase binding group, a linker and a protein binding group. PROTAC ER α Degradar-1 extracts from patent WO2017201449A1, compound P1. PROTAC ER α Degradar-1 is an estrogen receptor-alpha (ER α) degrader.

Treatment of the HER2 expressing cells with the PROTAC ER α Degradar-1 (without Ab; compound P1) results in a decreased estrogen receptor-alpha (ER α) levels[1].

[1]. Thomas Pillow, et al. Protac antibody conjugates and methods of use. WO2017201449A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA